Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:30 AM.
Here’s what investors need to know about the announcement.
Earnings
Arbutus Biopharma beat estimated earnings by 28.57%, reporting an EPS of $-0.1 versus an estimate of $-0.14.
Revenue was down $5.89 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.01 which was followed by a 1.78% increase in the share price the next day.
Here’s a look at Arbutus Biopharma’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.13 | -0.13 | -0.13 | -0.16 |
| EPS Actual | -0.14 | -0.12 | -0.10 | -0.11 |
| Revenue Estimate | 6.17M | 9.37M | 6.77M | 4.37M |
| Revenue Actual | 6.25M | 5.95M | 14.24M | 12.58M |
To track all earnings releases for Arbutus Biopharma visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
